Connor, Clark & Lunn Investment Management (CC&L)’s C4 Therapeutics CCCC Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.4M	Buy	300,734 +23,551	+8%	+$80.6K	﹤0.01%	1104
2026 Q1	$729K	Buy	277,183 +239,462	+635%	+$564K	﹤0.01%	1229
2025 Q4	$72K	Buy	+37,721	New	+$89.4K	﹤0.01%	1494
2024 Q2	–	Sell	-174,356	Closed	-$1.42M	–	1408
2024 Q1	$1.42M	Buy	174,356 +6,138	+4%	+$47.6K	0.01%	781
2023 Q4	$950K	Buy	168,218 +3,496	+2%	+$7.97K	﹤0.01%	876
2023 Q3	$306K	Sell	164,722 -9,637	-6%	-$29.4K	﹤0.01%	1139
2023 Q2	$479K	Buy	174,359 +60,466	+53%	+$194K	﹤0.01%	992
2023 Q1	$358K	Buy	113,893 +99,436	+688%	+$585K	﹤0.01%	972
2022 Q4	$85.3K	Buy	+14,457	New	+$120K	﹤0.01%	1119

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CCCC Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its C4 Therapeutics (CCCC) stake by 8.5% in Q2 2026, buying an estimated $80.6K and bringing the position to 300,734 shares worth $1.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1104.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CCCC in Q4 2022 and has held it in 9 quarters since. The position peaked at $1.42M in Q1 2024. 147 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 300,734 shares of C4 Therapeutics worth $1.4M as of Q2 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 23,551 C4 Therapeutics shares in Q2 2026, an estimated $80.6K.
C4 Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1104 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in C4 Therapeutics in Q4 2022 and has held it in 9 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s C4 Therapeutics position peaked at $1.42M in Q1 2024.
147 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.